Anticancer and Immuno-Modulating Properties of Cyclophosphazenes

Abstract

Abstract Clinical uses of aziridinocyclophosphazenes (“nude” drugs) as anticancer immuno-modulating drugs are severely limited by hematological toxicity. Benefits from vectorization through covalent linkage to biogenic polyamines as tumor finders are evidenced and further improvements through monoclonal antibodies are envisaged.